Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sun Pharma Shines Again With Re-launched Starhaler; Aims For U.S. IND Filing Next Year

This article was originally published in PharmAsia News

Executive Summary

Slowly but surely the Indian company is advancing its innovative drug pipeline.

You may also be interested in...



Teva Launches Generic Salmeterol in the U.K. To Compete With GSK's Serevent

The "first to market" generic salmeterol inhaler, which Teva is pricing at a 15% discount to Serevent, might help to pave the way for a much more lucrative opportunity - generic Advair.

Merck Emerging Markets President Kevin Ali On The Branded Generics Business: An Interview With PharmAsia News (Part 1 of 2)

When Merck & Co. Inc. Emerging Markets President Kevin Ali speaks of innovation, it is emblematic of Merck's deep-rooted focus on new drug discovery, but the veteran executive now sees opportunities in the differentiated, branded generics segment. On a recent visit to India, Ali spoke to PharmAsia News' India Bureau about incrementally innovative drugs, access to affordable medicines and also Merck's plans in the BRIC-MT nations.

Merck Establishes JV With India's Sun Pharma To Develop Novel Combinations Of Branded Generics For Emerging Markets

MUMBAI - Merck & Co. is establishing a joint venture with India's Sun Pharmaceutical Industries Ltd. for a broad-based alliance to develop, manufacture and commercialize novel combinations and "incrementally innovative" branded generics in emerging markets, the two companies announced April 11

Topics

Related Companies

UsernamePublicRestriction

Register

SC081836

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel